Humanigen, Inc. - Common Stock (NQ:HGEN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 25, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Humanigen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Why Did Humanigen's Stock Dump Today And What's Next? ↗

September 09, 2021

Humanigen Inc. (NASDAQ:HGEN) shares are trading sharply lo...

Via Benzinga

Mid-Day Market Update: Torrid Surges After Q2 Results; Humanigen Shares Slide ↗

September 09, 2021

Midway through trading Thursday, the Dow traded up 0.10% to 35,067.66 while the NASDAQ rose 0.20% to 15,316.45. The S&P also rose, gaining 0.04% to 4,516.10. The U.S. has the...

Via Benzinga

Topics Stocks

Here's Why Humanigen Is Getting Hammered Today ↗

September 09, 2021

An attempt to earn authorization for lenzilumab hit a wall at the FDA.

Via The Motley Fool

35 Stocks Moving In Thursday's Mid-Day Session ↗

September 09, 2021

Gainers Gevo, Inc. (NASDAQ: GEVO) shares climbed 36.6% to $7.91. Chevron and Gevo announced intent to pursue sustainable aviation fuel investment. Offerpad Solutions Inc (NYSE:...

Via Benzinga

Understanding Humanigen's Unusual Options Activity ↗

August 10, 2021

Humanigen (NASDAQ:HGEN) shares experienced unusual option...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021 ↗

September 09, 2021

Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE:

Via Benzinga

Mid-Morning Market Update: Markets Rise; Jobless Claims Fall To 310,000 ↗

September 09, 2021

Following the market opening Thursday, the Dow traded up 0.36% to 35,158.32 while the NASDAQ rose 0.41% to 15,348.81. The S&P also rose, gaining 0.26% to 4,525.59. The U.S....

Via Benzinga

Topics Stocks

Humanigen Stock Pummeled After FDA Rejects Its Experimental Covid Drug ↗

September 09, 2021

The Food and Drug Administration rejected Humanigen's experimental Covid treatment on Thursday, sending HGEN stock into a dive.

Via Investor's Business Daily

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 09, 2021

Gainers Soligenix (NASDAQ:SNGX) stock increased by 22.85% to $1.29 during Thursday's pre-market session. The company's market cap stands at $51.7 million. Cardiff...

Via Benzinga

The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization ↗

September 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:...

Via Benzinga

21 Stocks Moving in Thursday's Pre-Market Session ↗

September 09, 2021

Gainers Cardiff Oncology, Inc. (NASDAQ: CRDF) rose 17.3% to $8.27 in pre-market trading after the company announced new data from its Phase 1b/2 trial in KRAS-mutated metastatic...

Via Benzinga

See Why Humanigen Stock Is Plunging To 52-Week Low ↗

September 09, 2021

The FDA declined Humanigen Inc's (NASDAQ: HGEN) request for emergency use authorization (EUA) of its lenzilumab drug to treat newly hospitalized COVID-19...

Via Benzinga

FDA has declined Humanigen’s Emergency Use Authorization (EUA) Request for Lenzilumab in Hospitalized COVID-19 Patients

September 09, 2021

From Humanigen, Inc.

Via Business Wire

Analyzing Humanigen's Unusual Options Activity ↗

August 16, 2021

Humanigen (NASDAQ:HGEN) shares experienced unusual options activity on Monday. The stock price moved down to $16.48 following the option alert. Sentiment: BULLISH Option Type:...

Via Benzinga

Humanigen Reports Second Quarter 2021 Financial Results

August 12, 2021

From Humanigen, Inc.

Via Business Wire

I-Mab Stock Is Trading Lower After Unveiling Mid-Stage Trial Data Of Plonmarlimab In Hospitalized COVID-19 Patients ↗

August 11, 2021

I-Mab (NASDAQ: IMAB) has announced interim data from its Phase 2/3 study evaluating plonmarlimab (TJM2 or TJ003234) for cytokine release syndrome (CRS) in patients...

Via Benzinga

Humanigen's COVID-19 Candidate Shows 2.5 Fold Increase In Survival Without Ventilation ↗

August 04, 2021

Humanigen Inc (NASDAQ: HGEN) has announced an analysis of results from its Phase 3 LIVE-AIR study of lenzilumab in hospitalized patients with COVID-19. Data...

Via Benzinga

Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients

August 04, 2021

From Humanigen, Inc.

Via Business Wire

NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19

July 30, 2021

From Humanigen, Inc.

Via Business Wire

Humanigen’s Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study of Lenzilumab

July 22, 2021

From Humanigen, Inc.

Via Business Wire

Unusual Options Activity Insight: Humanigen ↗

July 19, 2021

Shares of Humanigen (NASDAQ:HGEN) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved up to $16.85. Sentiment: BEARISH Option...

Via Benzinga

Humanigen Stock Jumps As Lenzilumab Application Is Under Review In UK For COVID-19 ↗

July 09, 2021

The U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted for review Humanigen Inc's (NASDAQ: HGEN) marketing application seeking...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 09, 2021

Gainers Galectin Therapeutics (NASDAQ:GALT) shares moved upwards by 47.46% to $4.07 during Friday's pre-market session. The market value of their outstanding shares is...

Via Benzinga

The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO ↗

July 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc...

Via Benzinga

UK’s MHRA accepts Humanigen’s submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review

July 09, 2021

From Humanigen, Inc.

Via Business Wire

Humanigen Inc. Added to Russell 3000(R) Index

June 28, 2021

Burlingame, California--(Newsfile Corp. - June 28, 2021) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing...

Via Newsfile

Topics Derivatives Regulatory Compliance

Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA)

June 14, 2021

From Humanigen, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021 ↗

June 11, 2021

Upgrades Barclays upgraded the previous rating for Ventas Inc (NYSE:VTR) from Equal-Weight to Overweight. In the first quarter, Ventas showed an EPS of $0.72, compared to...

Via Benzinga

Why This COVID-19 Stock Is On Fire Right Now ↗

June 11, 2021

While vaccines and diagnostics have been the big winners in the space so far, Humanigen might make investors a lot of money with its drug to treat cytokine storms caused by COVID-19.

Via The Motley Fool

Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations

June 07, 2021

From Humanigen, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.